Nanoparticle-Mediated Strategies for Targeted Drug Transport Across the Blood–Brain Barrier

Rushikesh S. Chavan, Sanchi D. Kamble
Department of Pharmacy, K.T. Patil College of Pharmacy Dharashiv-413501

Abstract: The blood–brain barrier (BBB) is a highly dynamic and selectively permeable interface that safeguards the central nervous system (CNS). It plays a vital role in protecting neural tissue from toxins, pathogens, and fluctuations in blood composition, while also regulating the transport of essential nutrients and maintaining overall brain homeostasis. At the same time, this remarkable protective function creates a major therapeutic challenge: most drugs cannot efficiently cross the BBB. In fact, conventional small molecules, peptides, proteins, and gene-based therapeutics generally fail to reach the brain in concentrations sufficient to achieve meaningful clinical effects. This limitation has significantly hindered the treatment of neurological conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, stroke, and brain tumors.

This review highlights recent progress in the field of NP-mediated drug transport across the BBB, presented in four key stages: (1) the structure and physiology of the BBB and the barriers it imposes to drug delivery; (2) nanoparticle platforms and targeting strategies; (3) preclinical models and progress toward clinical translation; and (4) future innovations, including gene-editing technologies and AI-guided nanomedicine.

Keywords: Brain, Nanoparticles, Blood brain barrier

INTRODUCTION

One of the biggest health problems of the twenty-first century is still neurological disorders. Globally, conditions such multiple sclerosis, stroke, glioblastoma, Parkinson's disease, and Alzheimer's disease significantly increase morbidity and mortality. The World Health Organization estimates that neurological illnesses collectively account for more disability-adjusted life years than cancer or cardiovascular disease, demonstrating the enormous cost on society. For the majority of these illnesses, genuinely effective pharmaceutical therapies are still elusive despite decades of research. One of the biggest obstacles to advancement is not a shortage of therapeutic chemicals, but rather the challenge of getting them to the brain's targeted site of action.

The blood–brain barrier (BBB), a highly developed structural and functional contact that shields neural tissue from dangerous substances circulating in the bloodstream, protects the central nervous system (CNS).The BBB, which is made up of astrocytic endfeet, pericytes, densely linked endothelial cells, and a basement membrane, strictly regulates what enters and leaves the brain microenvironment. Although this barrier is crucial for preserving neuronal homeostasis and shielding the brain from poisons, pharmaceutical intervention faces an almost insurmountable obstacle. Nearly 100% of big molecules, including peptides, proteins, and nucleic acids, and over 98% of tiny molecules are unable to pass through the blood-brain barrier in therapeutically significant quantities. What many researchers refer to as the "BBB bottleneck" in neuroscience medication development is the result of this mismatch between physiological restriction and therapeutic requirement.

There are real-life consequences when medications cannot be efficiently delivered to the central nervous system. For instance, because they are unable to build up inside the brain tumor mass, several anti-cancer drugs that exhibit effectiveness against glioblastoma cells in vitro entirely fail in patients. Similar to this, low BBB penetration causes significant reductions in the efficacy of promising monoclonal antibodies for Alzheimer's disease. These restrictions highlight the pressing need for novel delivery methods that either go around or take advantage of the BBB.

One of the most promising approaches to this problem is the use of nanoparticles. In general, materials engineered at the 1–200 nanometer scale are referred to as nanoparticles. These materials are frequently made of lipids, polymers, metals, or biological components. They can interact with biological systems in ways that traditional drug formulations cannot because of their small size and adjustable surface chemistry. Crucially, nanoparticles can be modified to release cargo in

response to stimuli in the brain microenvironment, decorated with targeting ligands, or engineered to take advantage of endogenous transport pathways at the BBB.

Delivery via nanoparticles has potential that goes beyond theory. Nanoparticle formulations have greatly enhanced the transport of nucleic acid therapies for genetic disorders, allowed the passage of neurotrophic factors for neurodegenerative diseases, and improved the delivery of chemotherapeutic agents to brain tumors in preclinical studies. Additionally, a number of nanoparticle systems are currently undergoing clinical trials, demonstrating their translational significance.

But there are still challenges ahead. The BBB itself is not a homogeneous entity; its permeability and transporter expression vary depending on brain region, age, disease state, and even circadian rhythm; additionally, systemic clearance mechanisms like the mononuclear phagocyte system can remove nanoparticles from circulation before they even reach the brain; therefore, rational design based on a thorough understanding of BBB biology is crucial. The mechanisms by which nanoparticles cross the blood-brain barrier, the primary classes of nanocarriers that have been studied thus far, and their uses in preclinical and clinical settings are all covered in detail in this review. We start by thoroughly examining BBB transport mechanisms that can be used to deliver drugs. Next, we look at nanoparticle platforms, targeting ligands, experimental models, safety issues, and translational challenges



Fig 1: Structure of Blood Brain Barier



Fig 2: Transverse section in BBB illustrating its cellular structure.

Mechanisms of Nanoparticle Transport Across the Blood–Brain Barrier:

It is a dynamic protective barrier that controls molecular entry through a number of tightly regulated mechanisms rather than acting as an impermeable wall. Since nanoparticles cannot naturally cross the barrier in large quantities, effective strategies take advantage of or imitate physiological transport pathways. Carrier-mediated transport, receptor-mediated transcytosis, adsorptive-mediated transcytosis, and physically induced disruption of the barrier are the four main categories of mechanisms that are usually taken into consideration. Nanoparticles can be designed to specifically take advantage of one or more of these pathways, each of which has its own advantages and disadvantages.



Fig 3: Schematic diagram of the various pathway across BBB.

Carrier-Mediated Transport (CMT)

One of the most basic ways that vital small molecules get across the blood-brain barrier is through carrier-mediated transport. Transporters for glucose, amino acids, nucleosides, and other metabolites essential for neuronal function are abundant in the endothelial cells that line the barrier. For example, brain endothelial cells exhibit high expression of the glucose transporter GLUT1 and the large neutral amino acid transporter LAT1. generally, nanoparticles are too big to use these transporters directly. However, they can successfully "hitchhike" on carrier-mediated pathways by affixing mimetic groups or small-molecule ligands to their surfaces. For instance, PLGA nanoparticles conjugated with glucose residues have shown improved GLUT1 transport, particularly when transporter activity is elevated in hypoglycemia. Similarly, it has been demonstrated that LAT1 engagement allows nanoparticles decorated with L-DOPA or other neutral amino acid analogs to cross.

Although promising, this approach has drawbacks: carrier-mediated systems are easily saturated, which can result in competition with endogenous substrates; additionally, incorrect ligand density or orientation on the nanoparticle surface may impede transporter recognition; however, careful design of CMT-mimicking nanoparticles has demonstrated a significant improvement in brain delivery of drugs that would otherwise fail to cross.

Receptor-Mediated Transcytosis (RMT)

Receptor-mediated transcytosis is perhaps the most actively explored mechanism for nanoparticle-based brain delivery. In this pathway, molecules such as transferrin, insulin, and lipoproteins naturally bind to receptors on brain endothelial cells. The ligand–receptor complex is then internalized into endocytic vesicles, trafficked across the cell, and released into the brain parenchyma.

Nanoparticles can exploit RMT by being functionalized with ligands that bind these receptors. For instance:

- Transferrin (Tf) and transferrin receptor (TfR): Liposomes and polymeric nanoparticles coated with transferrin or anti-TfR antibodies have shown increased uptake and brain distribution.
- Insulin receptor (INSR): Insulin or insulin-mimetic peptides attached to nanoparticles promote transport across INSR-mediated vesicular pathways.
- Low-density lipoprotein receptor-related protein 1 (LRP1): Peptides such as angiopep-2 are widely used for decorating nanoparticles, significantly improving CNS delivery of small molecules, proteins, and siRNA.

One of the strengths of RMT is its high capacity and relative specificity. However, not all receptor-ligand interactions guarantee successful transcytosis; some pathways lead to lysosomal degradation rather than transport. Furthermore, receptor expression levels differ across species and disease states, complicating translation from animals to humans. Optimizing ligand affinity and valency is thus crucial. Interestingly, moderate-affinity ligands sometimes perform better than high-affinity ones, as they avoid excessive retention in the endothelial cell and promote efficient release into the brain.

Adsorptive-Mediated Transcytosis (AMT)

Adsorptive-mediated transcytosis is propelled by electrostatic interactions between cationic molecules and the negatively charged glycocalyx of endothelial cells, whereas CMT and RMT depend on particular ligands. Positively charged nanoparticles, such as those coated with polycations (like polyethyleneimine) or cell-penetrating peptides (like TAT peptide), might lead to non-specific uptake into endothelial cells and subsequent transcytosis.

This technique does not necessitate the engineering of precise ligand-receptor interactions and is rather straightforward. When compared to CMT or RMT, it can attain greater uptake rates. However, there are risks associated with the lack of specificity: positively charged nanoparticles may interact with proteins and cells that are not intended targets, potentially causing toxicity or immune activation. Furthermore, haemolysis and serum instability have been linked to an excessive positive charge. AMT must therefore be carefully designed to strike a balance between efficiency and safety, even though it is appealing for some applications.

Physically Induced BBB Modulation

Physical methods can also momentarily increase the permeability of the blood-brain barrier, allowing nanoparticles to enter the brain in addition to biological mechanisms. Combining circulating microbubbles with focused ultrasound (FUS) is one of the most promising techniques. Tight junctions are mechanically disrupted by the oscillation of microbubbles in blood vessels when ultrasound waves are focused on a particular area of the brain. This creates temporary openings that allow nanoparticles to pass through. Crucially, this effect is reversible; barrier integrity is usually restored in a matter of hours.

Additionally, hyperthermia and magnetic fields are being investigated as supplementary techniques to direct or improve nanoparticle delivery. For instance, using external magnets to concentrate magnetic nanoparticles in particular brain regions may lessen systemic side effects. Because physical modulation techniques can target particular brain regions, like tumour sites, while maintaining the integrity of the BBB, they are particularly appealing. Long-term safety, possible inflammatory reactions, and the repeatability of these methods in clinical settings are still issues, though.

Comparative Considerations

Every transportation route has its own advantages and disadvantages. Carrier-mediated transport has a limited capacity but is very selective. Strong

transcytosis opportunities are provided by receptor-mediated pathways, but careful ligand design is necessary. While physical methods offer control but require external equipment and could create safety risks, adsorptive-mediated uptake is effective but non-specific. In reality, a lot of effective nanoparticle systems combine multiple approaches, such as combining ultrasound with receptor-targeted nanoparticles to optimise delivery.
Comprehending the interaction of these mechanisms is crucial for developing efficient drug carriers and forecasting their performance in various physiological and pathological contexts. BBB permeability and receptor expression are altered by diseases like Alzheimer's and stroke, so nanoparticle strategies need to be adjusted appropriately.

Nanoparticle Platforms and Targeting Strategies
Because their properties can be carefully designed to address the challenges of BBB penetration, nanoparticles represent an adaptive class of drug carriers. Lipid-based, polymeric, dendrimeric, inorganic, and biomimetic platforms all have different advantages as well as disadvantages. Choosing the best system for a particular therapeutic application requires an understanding of these distinctions. The primary nanoparticle platforms for BBB-targeted drug delivery are thoroughly reviewed in this section, which is followed by a summary of ligand-based approaches that enhance their targeting capacity.

Lipid-Based Nanoparticles

Liposomes
Liposomes are spherical vesicles with an aqueous core encircled by one or more phospholipid bilayers. They are some of the first and most thoroughly researched drug delivery nanocarriers. They can contain both hydrophilic molecules (in the core) and hydrophobic substances (in the lipid bilayer) due to their amphiphilic structure.
Targeting ligands like transferrin or angiopep-2 can be added to the surface of liposomes for BBB delivery in order to activate receptor-mediated transcytosis. PEGylation, or polyethylene glycol coating, is frequently employed to increase circulation time and decrease mononuclear phagocyte system recognition. Although BBB-specific applications are still being researched, clinical formulations like Doxil® show the translational potential of liposomes.
Although liposomes are highly biocompatible and scalable, there are still issues with their stability in circulation and propensity for drug leakage. CNS drug delivery may benefit from recent developments in stimuli-responsive liposomes, which release cargo in response to pH, temperature, or enzymatic triggers.

Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs)
While NLCs combine solid and liquid lipids to form a less ordered matrix, SLNs are made up of solid lipids stabilised by surfactants. Both systems' biocompatibility, capacity to shield labile medications, and comparatively low toxicity make them appealing for BBB delivery.
Antipsychotics, anti-epileptic medications, and neuroprotective agents have all been studied for delivery via SLNs. But they frequently have a poor ability to load drugs. By adding liquid lipids, which produce flaws in the crystalline matrix and enable higher drug incorporation, NLCs get around this restriction. Both platforms can be coated with surfactants like polysorbate 80, which has been demonstrated to improve BBB crossing via apolipoprotein adsorption, or functionalised with targeting ligands.

Polymeric Nanoparticles
One of the most flexible and thoroughly researched platforms for CNS drug delivery is polymeric nanoparticles. By changing the polymer type and formulation technique, their characteristics, such as size, degradation rate, and surface chemistry, can be precisely altered.

PLGA Nanoparticles
PLGA nanoparticles are often PEGylated or conjugated with ligands like transferrin, lactoferrin, or antibodies against endothelial receptors for BBB applications. The FDA has approved poly (lactic-co-glycolic acid) (PLGA), a biodegradable polymer that is frequently used in drug delivery. Numerous biologics and small molecules can be encapsulated in PLGA nanoparticles, which offer controlled release and defence against enzymatic degradation.
Preclinical research has demonstrated that PLGA nanoparticles can enhance the brain delivery of medications for neurodegenerative diseases and glioblastoma. Although large-scale reproducibility and ligand stability are still important factors, their biodegradability and proven safety profile make them very appealing for clinical translation.

Chitosan and Other Natural Polymers

Adsorptive-mediated transcytosis is made possible by the intrinsic cationic nature of chitosan, a polysaccharide that is derived from chitin. Chitosan nanoparticles can improve paracellular transport by momentarily opening tight junctions. Additionally, they are mucoadhesive and biodegradable, which makes them beneficial for intranasal delivery methods that completely avoid the BBB.

Alginate and gelatin are two more natural polymers that have been investigated. When biocompatibility is crucial, these carriers are frequently taken into account for combination strategies and sustained-release formulations.

Synthetic Polymers and Copolymers

Synthetic polymers like polycaprolactone (PCL), poly (alkyl cyanoacrylates), and PEG-based copolymers have been investigated in addition to PLGA and chitosan. Degradation rates, mechanical characteristics, and hydrophilic/hydrophobic balance can all be adjusted with these systems. Certain copolymers have the ability to self-assemble into micelles, which are especially helpful for transporting hydrophobic medications across the blood-brain barrier.

Dendrimers

Dendrimers are highly branched, tree-like polymers with surface functional groups and precise architecture. They are particularly intriguing for brain-targeted delivery because of their monodispersity and controllable size.

Drugs, imaging agents, or targeting ligands can be incorporated into the terminal groups of dendrimers. To improve BBB penetration, for instance, poly(amidoamine) (PAMAM) dendrimers have been conjugated with ligands like transferrin and peptides. Because of their multivalency, "theranostic" applications are made possible by the simultaneous attachment of therapeutic and diagnostic molecules

However, haemolysis, immunological activation, and toxicity can result from the cationic nature of many dendrimers. To lessen these effects, surface modifications like acetylation or PEGylation are frequently used. Dendrimers continue to show promise for applications requiring high precision and multifunctionality in spite of these limitations.

Inorganic Nanoparticles

Gold, iron oxide, silica, and quantum dots are examples of inorganic nanoparticles with special optical, magnetic, or electrical characteristics that make them appealing for theranostics and imaging.

Gold Nanoparticles (AuNPs)

Gold nanoparticles can be produced in a range of sizes and shapes and are biocompatible. It is simple to functionalise their surface using nucleic acids, ligands, or antibodies. AuNPs' strong plasmon resonance makes them particularly useful for imaging applications. AuNPs conjugated with peptides like RVG29 have demonstrated a promising ability to cross the blood-brain barrier in brain delivery.

Magnetic Nanoparticles

Iron oxide nanoparticles are particularly well-suited for targeted delivery because they can be directed to particular brain regions using external magnetic fields. Additionally, they act as contrast agents for magnetic resonance imaging (MRI), allowing distribution to be tracked in real time. Although encouraging, oxidative stress and long-term accumulation are still hot research topics.

Silica and Other Nanomaterials

Due to their large surface area and adjustable pore sizes, mesoporous silica nanoparticles enable effective drug loading and regulated release. In contrast to organic nanoparticles, their long-term biocompatibility is less well-established. Despite being helpful for imaging, the heavy metal content of quantum dots raises toxicity concerns.

Biomimetic Nanoparticles

Biomimetic approaches seek to exploit the body’s own mechanisms for crossing the BBB. Exosomes, nanoparticles coated in cell membranes, and carriers inspired by viruses fall under this category.

Exosomes

Exosomes are natural extracellular vesicles secreted by cells that play a role in intercellular communication. They are naturally able to pass through the blood-brain barrier, most likely via receptor-mediated processes. Researchers can achieve highly effective brain delivery with low immunogenicity by isolating exosomes from particular cell types and loading them with therapeutic agents. Standardisation and large-scale

production, however, continue to be significant obstacles.

Cell Membrane-Coated Nanoparticles

Coating artificial nanoparticles with natural cell membranes, such as those from red blood cells, leukocytes, or platelets, is another promising tactic. Immune evasion, extended circulation, and occasionally intrinsic targeting ability are all provided by these biomimetic coatings. To achieve homotypic targeting for BBB delivery, coating with membranes derived from neurones or brain endothelial cells has been investigated.

Virus-Inspired Nanocarriers

Viruses are nature's most efficient delivery vehicles. Researchers can take advantage of viruses' innate capacity to penetrate cells and cross barriers by imitating viral structures or creating virus-like particles (VLPs). Crucially, these systems are made to be both functional and non-infectious.

Targeting Ligands

While the physicochemical properties of nanoparticles play a role in BBB crossing, active targeting with ligands dramatically enhances efficiency and specificity. Frequently used ligands consist of:

- Transferrin and anti-TfR antibodies – exploit transferrin receptor pathways.
- Lactoferrin – targets both TfR and other receptors, with demonstrated BBB penetration.
- Angiopep-2 – a peptide ligand for LRP1, widely used in clinical-stage formulations.
- Insulin and insulin-mimetic peptides – leverage INSR-mediated pathways.
- Apolipoproteins (e.g., ApoE fragments) – mimic natural lipoproteins that cross the BBB.
- RVG29 peptide – derived from rabies virus glycoprotein, facilitates neuronal targeting.
- Cell-penetrating peptides (e.g., TAT) – promote adsorptive-mediated uptake.

The choice of ligand must consider not only receptor expression and trafficking pathways but also affinity. Interestingly, extremely high-affinity ligands can cause nanoparticles to become trapped in endothelial cells rather than being transcytosed. Thus, ligand density and binding strength require careful optimization.

Multifunctional strategies are also emerging, where nanoparticles are decorated with two or more ligands targeting different receptors. This approach can enhance efficiency and overcome receptor heterogeneity across the BBB.

Comparative Evaluation

No single nanoparticle platform is universally superior. Instead, the choice depends on the therapeutic cargo, disease context, and clinical requirements:

- Liposomes excel in biocompatibility but face stability issues.
- Polymeric nanoparticles offer controlled release and versatility, with PLGA being the most clinically promising.
- Dendrimers allow precision and multifunctionality but can be toxic.
- Inorganic nanoparticles are powerful for imaging but raise long-term safety questions.
- Biomimetic systems promise unmatched targeting but struggle with scalability.

Future directions likely involve hybrid systems that combine the strengths of multiple platforms—for example, polymeric cores coated with cell membranes or inorganic nanoparticles encapsulated in liposomes.

Experimental Models for Studying BBB Transport

A critical challenge in the development of BBB-targeted nanoparticle systems is the lack of models that perfectly replicate the complexity of the human blood–brain barrier. While animal studies remain central, the scientific community increasingly relies on complementary in vitro and ex vivo models to predict human outcomes. Here, we explore the main categories of models, their strengths, and their limitations.

In Vitro Models

Transwell-Based Endothelial Models

The most widely used in vitro BBB models employ brain endothelial cells cultured on semipermeable membranes in transwell chambers. These cells develop tight junctions and exhibit some of the barrier properties seen in vivo. By co-culturing with astrocytes and pericytes, researchers can better mimic the neurovascular unit.

Transwell models allow rapid, reproducible screening of nanoparticle permeability and uptake. However, they fail to fully reproduce the dynamic mechanical forces, three-dimensional structure, and heterogeneity of the human BBB.

Microfluidic "Organ-on-a-Chip" Platforms

Recent advances in microfluidics have enabled BBB-on-a-chip devices, where endothelial cells are grown under flow conditions that replicate shear stress. These systems can incorporate astrocytes, pericytes, and even neurons, creating a closer approximation to the in vivo microenvironment.
Such platforms allow real-time imaging of nanoparticle transport and can be customized with human-derived cells, offering superior predictive power compared to static transwells. However, fabrication complexity and lack of standardization remain hurdles to widespread adoption.

Stem Cell-Derived BBB Models
Human-induced pluripotent stem cells (iPSCs) can be differentiated into endothelial cells with BBB-like properties. These cells, when combined with astrocytes and pericytes, produce models that capture species-specific features of human BBB physiology.
This is particularly important because many therapies that succeed in rodent BBB models fail in humans due to interspecies differences. Stem cell-derived models are rapidly becoming the gold standard for translational BBB research.

In Vivo Models

Rodent Models
Rodents, particularly mice and rats, are the backbone of in vivo BBB research. Their small size, genetic tractability, and well-characterized physiology make them highly convenient. Transgenic models of neurological diseases, such as Alzheimer's or Parkinson's disease, allow researchers to test nanoparticle delivery in disease-relevant contexts.
However, rodent BBB characteristics—such as transporter expression, metabolic activity, and tight junction composition—differ from humans. This contributes to the translational gap between preclinical success and clinical failure.

Non-Rodent Models
Larger animals, including rabbits, dogs, and primates, provide closer physiological parallels to the human BBB. Non-human primates are particularly valuable due to their similarity in vascular structure, receptor expression, and immune responses. However, ethical considerations, high costs, and logistical challenges limit their use to later-stage studies.

Disease Models
In addition to healthy animals, disease-specific models play a critical role. For example, stroke and traumatic brain injury models mimic BBB disruption, while transgenic mice with amyloid or tau pathology are used for Alzheimer's research. Glioblastoma xenografts in rodents are also common for testing anti-cancer nanoparticles.

Ex Vivo and Computational Models

Isolated Brain Perfusion
In this approach, the brain vasculature of an animal is perfused with nanoparticles under controlled conditions. This allows direct assessment of BBB permeability without systemic variables.

Brain Slices and Organotypic Cultures
Brain slice cultures preserve the three-dimensional architecture of the neurovascular unit, enabling short-term studies of drug penetration and cellular interactions.

Computational and In Silico Models
Mathematical modeling and molecular simulations are increasingly used to predict nanoparticle transport across the BBB. These approaches integrate data from in vitro and in vivo studies to guide design decisions before expensive animal testing.

Safety Considerations in BBB Nanomedicine
The promise of nanoparticle-mediated delivery must be balanced against potential risks. Safety evaluation is essential not only for regulatory approval but also for public acceptance. Here, we outline key safety concerns and how they are being addressed.

Immunogenicity and Inflammation
Nanoparticles may interact with the immune system in unintended ways. Certain materials—such as cationic polymers or unmodified inorganic nanoparticles—can trigger cytokine release, complement activation, or microglial activation in the brain.
Surface modifications like PEGylation or biomimetic coatings reduce immune recognition. Exosomes and cell membrane-coated nanoparticles are especially attractive due to their inherent low immunogenicity. Nonetheless, immune responses vary depending on dose, route of administration, and disease state.

Neurotoxicity
Potential neurotoxic effects include oxidative stress, mitochondrial dysfunction, and disruption of

neuronal signaling. Inorganic nanoparticles, such as quantum dots and some iron oxide formulations, raise particular concerns due to their long-term persistence in tissue.

Polymers like PLGA degrade into lactic and glycolic acid, which are naturally metabolized, minimizing toxicity risks. Rigorous neurotoxicity testing—including electrophysiological assessments and behavioral studies—is critical before translation.

Hemocompatibility and Vascular Safety

Nanoparticles in systemic circulation may interact with blood components, leading to hemolysis, platelet aggregation, or coagulation abnormalities. These effects can compromise both systemic safety and cerebral perfusion.

Surface charge plays a major role: highly positive or negative zeta potentials are associated with greater risks. Neutral or slightly negative particles are generally preferred for intravenous administration.

Biodistribution and Clearance

Understanding where nanoparticles go after administration is critical. Ideally, they should accumulate in the brain and clear safely without long-term tissue retention. However, many systems are prone to uptake by the liver, spleen, and kidneys. Advanced imaging techniques—such as PET, MRI, and optical imaging—allow non-invasive tracking of biodistribution. Designing biodegradable carriers, optimizing size (typically 20–100 nm for BBB transport), and employing active targeting strategies improve safety profiles.

Regulatory Safety Framework

Agencies such as the FDA and EMA require extensive toxicological data, including acute and chronic toxicity, genotoxicity, reproductive safety, and immunotoxicity. Because nanomedicines fall between conventional drugs and medical devices, regulatory frameworks are still evolving. Developers must navigate both pharmaceutical and materials science standards, which can slow clinical translation.

Clinical Applications and Translational Progress

Despite the challenges, several nanoparticle systems have advanced into clinical trials for CNS diseases. These examples highlight both the potential and the remaining barriers to full-scale implementation.

Glioblastoma and Brain Tumors

Glioblastoma multiforme (GBM) is one of the deadliest brain cancers, partly due to poor drug penetration across the BBB. Nanoparticles have been explored to deliver chemotherapeutics, siRNA, and radiosensitizers directly to tumors.

- ANG1005, a paclitaxel–angiopep-2 conjugate, successfully entered Phase II/III trials and showed improved brain penetration.
- Liposomal doxorubicin and PLGA nanoparticles encapsulating temozolomide are being tested in preclinical and early clinical stages.
- Nanoparticles combined with focused ultrasound (FUS) have been investigated to transiently open the BBB at tumor sites, further improving delivery.

Neurodegenerative Diseases

Alzheimer's and Parkinson's diseases represent major unmet needs in neurology.

- Alzheimer's disease: Nanoparticles carrying anti-amyloid or anti-tau antibodies, as well as siRNA or CRISPR-based constructs, are being tested in animal models. Liposomes and exosomes targeting LRP1 have shown promise in reducing amyloid plaque burden.
- Parkinson's disease: Dopamine replacement remains a challenge due to poor BBB penetration. Nanoparticle-based delivery of levodopa, neurotrophic factors, and gene therapies is under exploration. Exosome carriers have shown ability to deliver alpha-synuclein-targeting molecules into neurons.

Stroke and Ischemic Injury

Stroke causes both BBB disruption and neuroinflammation, making it a prime target for nanoparticle therapy. Antioxidant-loaded nanoparticles, magnetic particles carrying thrombolytics, and dendrimer-based anti-inflammatory agents are being evaluated.

Because the BBB is temporarily disrupted in stroke, nanoparticles can more readily access the brain. However, timing and dosing must be carefully controlled to avoid exacerbating damage.

Psychiatric Disorders

Depression, schizophrenia, and anxiety disorders have also been explored as targets for nanoparticle therapeutics. Delivering antidepressants or antipsychotics in nanoparticle form may reduce systemic side effects and improve CNS bioavailability.

Clinical progress remains limited, but intranasal nanoparticle delivery—bypassing the BBB via olfactory and trigeminal pathways—has gained attention for psychiatric indications.

Rare and Genetic Disorders

Lysosomal storage diseases and other rare neurological conditions often lack effective therapies due to the BBB barrier. Nanoparticles are being studied for enzyme replacement and gene delivery approaches. For example, nanoparticle-based gene therapies hold promise for conditions like metachromatic leukodystrophy and spinal muscular atrophy.

Disease	Drug	Nanoformulation	Advantages
Alzheimer's	Curcumin, Donepezil, Rivastigmine	SLNs, Chitosan NPs, NLCs	Improved memory, reduce plaque deposition
Parkinson's	Dopamine, Levodopa	PLGA nanoparticles, Liposomes	Enhanced dopamine supply to neurons
Brain Tumor (Glioblastoma)	Doxorubicin, Paclitaxel, siRNA	Liposomes, Gold NPs, Magnetic NPs	Targeted delivery, reduce systemic toxicity
Epilepsy	Carbamazepine, Valproate	Polymeric nanoparticles	Controlled drug release, fewer seizures
Stroke	Neuroprotective peptides, siRNA	Exosomes, Liposomes	Reduce inflammation, promote repair

Table 1: Application of nanoformulation in brain disease

Challenges in Clinical Translation

Although progress has been made, the path from laboratory to clinic remains steep. Key challenges include:

- Scalability: Producing nanoparticles under Good Manufacturing Practice (GMP) conditions at clinical scale remains difficult.
- Reproducibility: Small changes in formulation can significantly alter BBB penetration and safety profiles.
- Heterogeneity of the BBB: Disease states alter BBB properties, complicating predictions of nanoparticle performance.
- Regulatory uncertainty: Lack of harmonized global standards slows approvals.
- Cost: Advanced nanoparticle therapies may be prohibitively expensive for widespread use.

Disease-Specific Applications of BBB-Targeted Nanoparticles

The central nervous system is affected by a wide variety of disorders, each with unique pathophysiological features. A one-size-fits-all strategy for drug delivery is thus unrealistic. Instead, nanotechnology platforms are being tailored to meet disease-specific needs. Below, we examine the major categories of brain disorders where nanoparticle-mediated delivery has shown promise.

Glioblastoma and Other Brain Tumors

Glioblastoma multiforme (GBM) is the most aggressive and lethal form of brain cancer, with a median survival of less than 18 months despite multimodal therapy. One of the greatest obstacles to effective treatment is the BBB, which prevents adequate accumulation of chemotherapeutics at the tumor site. Nanoparticles offer multiple advantages in this context.

- Enhanced Permeability and Retention (EPR) Effect: Tumor vasculature is often leaky, allowing nanoparticles to accumulate more readily than small molecules.
- Active Targeting: Ligands such as transferrin, angiopep-2, and folate have been conjugated to nanoparticles to enhance tumor-specific uptake.
- Multifunctional Platforms: Some nanoparticle formulations combine therapeutic and diagnostic capabilities ("theranostics"), allowing imaging and treatment simultaneously.

Clinical examples include ANG1005, a paclitaxel-derivative conjugated to angiopep-2, which demonstrated improved penetration and efficacy in Phase II trials. Liposomal temozolomide and doxorubicin formulations are under investigation, while gold nanoparticles are being tested for photothermal ablation of tumor tissue.

Nevertheless, challenges remain: tumor heterogeneity, drug resistance, and immunosuppressive microenvironments limit long-term success. Combination therapies—where nanoparticles deliver chemotherapy alongside immunomodulators or radiosensitizers—may overcome these barriers.

Alzheimer's Disease

Alzheimer's disease (AD) is characterized by amyloid-beta plaques, tau tangles, and progressive synaptic dysfunction. Traditional drugs for AD provide only modest symptomatic relief, in part due to poor BBB penetration.

Nanoparticle strategies in AD include:

- Anti-Amyloid Therapies: Liposomes and polymeric nanoparticles carrying monoclonal antibodies or siRNAs targeting amyloid-beta production.
- Tau-Targeting Approaches: Dendrimers and exosomes delivering anti-tau molecules.
- Gene and CRISPR Delivery: Nanoparticles transporting CRISPR-Cas9 systems to edit APP or tau-related genes.
- Antioxidant Delivery: Polymeric nanoparticles encapsulating curcumin, resveratrol, or other neuroprotective agents to counter oxidative stress.

Clinical translation remains limited, but early animal studies show improved memory function and reduced plaque burden. Importantly, nanoparticle formulations reduce peripheral side effects of drugs by limiting systemic exposure.

Parkinson's Disease

Parkinson's disease (PD) involves progressive dopaminergic neuron loss in the substantia nigra. Dopamine itself cannot cross the BBB, forcing reliance on levodopa, which has variable efficacy and long-term complications.

Nanoparticles offer several solutions:

- Sustained Dopamine Delivery: Polymeric carriers for controlled release of dopamine or dopamine precursors.
- Neurotrophic Factor Delivery: Nanoparticles carrying glial-derived neurotrophic factor (GDNF) or brain-derived neurotrophic factor (BDNF) to support neuronal survival.
- Gene Therapies: Nanoparticles delivering genes that enhance dopamine synthesis or reduce alpha-synuclein accumulation.
- Intranasal Delivery: Bypassing the BBB through olfactory pathways using nanocarriers for rapid central action.

Some preclinical studies show substantial motor improvement and reduced neurodegeneration in PD models, suggesting a pathway toward clinical trials.

Stroke and Ischemic Brain Injury

Stroke remains a leading cause of death and disability worldwide. The BBB is often compromised after ischemia, but this disruption is heterogeneous and transient. Nanoparticles have been investigated to deliver thrombolytics, antioxidants, and anti-inflammatory agents.

- Thrombolytic Nanoparticles: Encapsulation of tissue plasminogen activator (tPA) reduces systemic bleeding risk and enhances clot dissolution at the target site.
- Antioxidant Delivery: Nanoparticles carrying edaravone, curcumin, or catalase help counteract reperfusion injury.
- Dendrimer-Based Therapies: Dendrimers accumulate at injury sites and deliver anti-inflammatory payloads to microglia.

A major challenge is timing: late administration of nanoparticles may worsen cerebral edema or hemorrhage. Personalized imaging-guided strategies may optimize outcomes.

Psychiatric and Neurodevelopmental Disorders

Depression, schizophrenia, and autism spectrum disorders are increasingly being explored as targets for nanomedicine. Traditional psychotropics often have poor CNS bioavailability and systemic side effects.

- Antidepressants: Solid lipid nanoparticles and nanocrystals improve bioavailability of SSRIs and SNRIs.
- Antipsychotics: Liposomal risperidone and aripiprazole nanoparticles show improved delivery in animal models.
- Intranasal Delivery: Offers rapid onset of action and avoids systemic metabolism.

While still in the experimental stage, these approaches could revolutionize psychiatric pharmacotherapy by reducing side effects and improving efficacy.

Rare and Genetic Disorders

Nanoparticles are also being developed for rare lysosomal storage diseases and genetic neurodegenerative disorders.

- Enzyme Replacement: Nanoparticles protect fragile enzymes and deliver them across the BBB.
- Gene Therapy: Non-viral nanoparticle systems offer safer alternatives to viral vectors for delivering therapeutic genes.
- Spinal Muscular Atrophy and Leukodystrophies: Nanoparticles carrying oligonucleotides or gene-editing tools hold promise for these otherwise untreatable conditions.

Such applications are still mostly in preclinical stages but represent one of the most exciting frontiers for nanomedicine.

Regulatory and Ethical Perspectives

As nanoparticle-based BBB delivery platforms move closer to clinical translation, regulatory and ethical considerations become increasingly important.

Regulatory Challenges

Nanomedicines often blur the line between drugs and devices, complicating approval processes. Agencies such as the FDA and EMA require rigorous data on:

- Pharmacokinetics and biodistribution.
- Long-term toxicity, especially neurotoxicity.
- Immunogenicity and off-target effects.
- Manufacturing reproducibility and scalability.

Harmonization of global standards is urgently needed, as fragmented regulations slow development. Establishing nanomedicine-specific guidelines could accelerate approvals while ensuring safety.

Ethical Considerations

Delivering drugs into the brain raises ethical questions not present in other therapeutic areas:

- Informed Consent: Patients must understand the long-term risks of experimental nanoparticle therapies.
- Privacy and Cognitive Liberty: CNS-active nanomedicines could alter mood, cognition, or behavior, raising philosophical concerns.
- Animal Testing: Non-human primate studies may be necessary but pose ethical dilemmas.
- Equity of Access: Nanomedicine therapies may be prohibitively expensive, exacerbating healthcare disparities.

Bioethics committees increasingly advocate for early dialogue between researchers, regulators, and patient groups to ensure responsible innovation.

Societal Impact

If successful, BBB-targeted nanoparticles could transform neurology and psychiatry, extending life expectancy and quality of life. However, widespread adoption requires addressing cost, accessibility, and societal perceptions of nanotechnology. Public engagement campaigns are recommended to build trust and dispel misconceptions.

Future Outlook

The field of BBB-targeted nanomedicine is advancing rapidly, driven by technological innovations and urgent clinical need. Several trends are likely to define the next decade.

Personalized Nanomedicine

Patient-specific factors such as genetics, age, sex, and disease state influence BBB properties. Personalized nanoparticles tailored to individual BBB characteristics may improve efficacy. Integration with biomarkers and AI-driven drug design could accelerate this trend.

Integration with Neurotechnology

The rise of brain–computer interfaces (BCIs) and implantable devices offers new possibilities. Nanoparticles could be combined with such devices to deliver drugs directly at neural interfaces, enabling highly targeted interventions for epilepsy, movement disorders, and even cognitive enhancement.

CONCLUSION

Nanoparticle-mediated delivery across the blood–brain barrier represents one of the most promising frontiers in modern medicine. From brain tumors to neurodegeneration and psychiatric disorders, these technologies offer the possibility of effective therapies where conventional drugs have failed.

Yet the path to clinical reality remains challenging. Safety, scalability, and ethical issues must be addressed alongside scientific innovation. With sustained interdisciplinary collaboration, BBB-targeted nanomedicine has the potential to transform neurology and psychiatry in the coming decades, offering hope to millions of patients worldwide.

REFERENCE

[1] Abbott NJ, Rönnbäck L, Hansson E. Astrocyte–endothelial interactions at the blood–brain barrier. *Nat Rev Neurosci.* 2006;7(1):41–53.

[2] Pardridge WM. The blood–brain barrier: bottleneck in brain drug development. *NeuroRx.* 2005;2(1):3–14.

[3] Daneman R, Prat A. The blood–brain barrier. *Cold Spring Harb Perspect Biol.* 2015;7(1):a020412.

[4] Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and dysfunction of the blood–brain barrier. *Cell.* 2015;163(5):1064–78.

[5] Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood–brain barrier. *Nat Med.* 2013;19(12):1584–96.

[6] Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: overcoming

blood–brain barrier to treat neurodegenerative diseases. *J Control Release.* 2016;235:34–47.

[7] Hersh DS, Wadajkar AS, Roberts N, Perez JG, Connolly NP, Frenkel V, et al. Evolving drug delivery strategies to overcome the blood–brain barrier. *Curr Pharm Des.* 2016;22(9):1177–93.

[8] Teleanu DM, Chircov C, Grumezescu AM, Volceanov A, Teleanu RI. Blood–brain delivery through nanoparticles. *Biomedicines.* 2018;6(3):61.

[9] Tosi G, Costantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, et al. Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. *J Control Release.* 2007;122(1):1–9.

[10] Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. *Acta Pharm Sin B.* 2016;6(4):268–86.

[11] Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. *Adv Drug Deliv Rev.* 2012;64(7):701–5.

[12] Saraiva C, Barrias CC, Nobre RJ, Bernardino L. Challenges in translating nanoparticles for brain delivery. *Front Neurosci.* 2021;15:633664.

[13] Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood–brain barrier: from physiology to disease and back. *Physiol Rev.* 2019;99(1):21–78.

[14] Nance EA, Woodworth GF, Sailor KA, Shih TY, Xu Q, Swaminathan G, et al. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. *Sci Transl Med.* 2012;4(149):149ra119.

[15] Banks WA. From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery. *Nat Rev Drug Discov.* 2016;15(4):275–92.

[16] Lockman PR, Koziara JM, Mumper RJ, Allen DD. Nanoparticle surface charges alter blood–brain barrier integrity and permeability. *J Drug Target.* 2004;12(9–10):635–41.

[17] Chen Y, Liu L. Modern methods for delivery of drugs across the blood–brain barrier. *Adv Drug Deliv Rev.* 2012;64(7):640–65.

[18] Kreuter J. Nanoparticulate systems for brain delivery of drugs. *Adv Drug Deliv Rev.* 2014;71:2–14.

[19] Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nanoscale drug delivery systems and the blood–brain barrier. *Int J Nanomedicine.* 2014;9:795–811.

[20] Liu Y, An S, Li J, Kuang Y, He X, Guo Y, et al. Brain-targeted delivery of therapeutic proteins using a nanocarrier system. *J Control Release.* 2014;190:637–45.

[21] Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nat Biotechnol.* 2015;33(9):941–51.

[22] Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Ipe BI, et al. Renal clearance of quantum dots. *Nat Biotechnol.* 2007;25(10):1165–70.

[23] Wang S, Su R, Nie S, Sun M, Zhang J, Wu D. Application of nanotechnology in enhancing bioavailability and bioactivity of dietary polyphenols. *J Nutr Biochem.* 2014;25(4):363–76.

[24] Li J, Zhang X, Wang M, Li W, Chen J. Angiopep-2 modified nanoparticles for brain-targeted drug delivery. *Curr Pharm Des.* 2020;26(13):1508–18.

[25] Bicker J, Alves G, Fortuna A, Falcão A. Blood–brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. *Eur J Pharm Biopharm.* 2014;87(3):409–32.

[26] Kuo YC, Chen YH. Entrapment and release of saquinavir using cationic solid lipid nanoparticles with surface anti-transferrin receptor monoclonal antibody. *Int J Pharm.* 2015;478(1):1–10.

[27] Loureiro JA, Andrade S, Duarte A, Neves AR, Queiroz JF, Nunes C, et al. Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer's disease. *Molecules.* 2017;22(2):277.

[28] Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood–brain barrier by nanoparticles. *J Control Release.* 2012;161(2):264–73.

[29] Pulgar VM. Transcytosis to cross the blood brain barrier, new advancements and challenges. *Front Neurosci.* 2019;13:1019.

[30] Sonali, Agrawal P, Singh RP, Raj R, Kumar M, Singh S, et al. Transferrin receptor-targeted polymeric nanoparticles for delivery of anticancer drugs. *Nanomedicine (Lond).* 2016;11(17):2379–401.

[31] Xin H, Sha X, Jiang X, Zhang W, Chen L, Fang X. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual-

targeting nanoparticles. *Biomaterials.* 2012;33(32):8167–76.

[32] Johnsen KB, Burkhart A, Melander F, Kempen PJ, Vejlebo JB, Siupka P, et al. Targeting transferrin receptors at the blood–brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma. *J Control Release.* 2017;268:304–17.

[33] Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. *Cancers (Basel).* 2019;11(5):640.

[34] Ye D, Jiang W, Zhu N, Su J, Wang L, Wu J, et al. Focused ultrasound combined with microbubble-mediated delivery of nanoparticles in brain cancer therapy. *J Control Release.* 2018;279:220–33.

[35] Aryal M, Arvanitis CD, Alexander PM, McDannold N. Ultrasound-mediated blood–brain barrier disruption for targeted drug delivery in the central nervous system. *Adv Drug Deliv Rev.* 2014;72:94–109.

[36] Pardridge WM. Blood–brain barrier drug delivery of small molecules and biologics: principles, strategies, and progress. *Neurotherapeutics.* 2020;17(3):571–601.

[37] Mager I, Meyer AH, Li J, Lötvall J, Wood MJ, Vader P. Extracellular vesicle-based therapeutics for the nervous system. *Trends Mol Med.* 2019;25(12):1079–94.

[38] van der Pol E, Boing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. *Pharmacol Rev.* 2012;64(3):676–705.

[39] Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. *Adv Pharm Bull.* 2015;5(3):305–13.

[40] Kang T, Jiang M, Jiang D, Feng X, Yao J, Song Q, et al. Enhancing brain delivery of nanoparticles by blood–brain barrier modulation. *J Control Release.* 2020;322:324–37.

[41] Modi G, Pillay V, Choonara YE, Ndesendo VM, du Toit LC, Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. *Prog Neurobiol.* 2009;88(4):272–85.

[42] Qiao R, Jia Q, Hüwel S, Xia R, Liu T, Gao F, et al. Receptor-mediated delivery of magnetic nanoparticles across the blood–brain barrier. *ACS Nano.* 2012;6(4):3304–10.

[43] Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. *Nat Rev Drug Discov.* 2014;13(11):813–27.

[44] Yu M, Zheng J. Clearance pathways and tumor targeting of imaging nanoparticles. *ACS Nano.* 2015;9(7):6655–74.

[45] Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. *Adv Drug Deliv Rev.* 2010;62(11):1064–79.

[46] Nasr M. Nanotechnology-based approaches in neurodegenerative disease therapy: recent trends and challenges. *Rev Neurosci.* 2019;30(3):305–26.

[47] Tiwari S, Goel A, Goel A. Nanomedicine for CNS disorders: a translational perspective. *Nanomedicine (Lond).* 2021;16(6):443–67.

[48] McMillan P, Boyd BJ. Nanomedicine for neurological disorders. *Nanomedicine (Lond).* 2015;10(12):1889–903.

[49] ong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. *Adv Drug Deliv Rev.* 2012;64(7):686–700.

[50] García-García E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood–brain barrier (BBB) translocation: a way to deliver drugs to the brain? *Int J Pharm.* 2005;298(2):274–92.